Dr. Anderson is the Austen Professor of Medicine at Harvard Medical School and serves as the SVP of Research and Education and Chief Academic Officer (CAO) at Brigham and Women’s Hospital. He is also the Dean of the Faculty at MGB for Harvard Medical School and is currently serving as the acting CAO at Mass General Brigham (MGB) managing a ~ $2B research enterprise. As acting CAO, he oversees several key system-wide departments at MGB, including Human Subjects Affairs, Clinical Trials Office, Research Management, Research IS Computing, Data Science Office, Personalized Medicine, Gene and Cell Therapy Institute and Graduate Medical Education. He has earned an international reputation in the area of post-transcriptional control of gene expression during stress and inflammatory responses. He discovered that a prion-related, low complexity domain in the RNA-binding protein TIA1 promotes a liquid phase transition leading to the assembly of stress granule (SGs), a class of membranless organelle that organizes cellular components and has been implicated in the pathogenesis of neurodegenerative disease. His related discovery that angiogenin (ANG)-induced tRNA fragments (tiRNAs) target the translation machinery to re-program gene expression and promote cell survival has been linked to motor neuron survival. He identified a tiRNA analogue with neuroprotective properties that is being developed for first in human studies in patients with ALS.